RLMD

Relmada Therapeutics Inc.

Price

$4.83

return (12m)

677.65%

p/e

-8.66

p/bv

2.60

DIVIDEND YIELD

0.00%

RLMD price

Relmada Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment RLMD

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-7.03%

3 months

-33.01%

1 year

677.65%

2 years

67.13%

5 years

-80.12%

10 years

-26.37%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals RLMD

Valuation

P/E

-8.66

Sector -4.38

Industry -4.38

P/BV

2.60

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-21.24

Sector -263.09

Industry -263.09

EV/EBIT

-21.24

Sector -702.90

Industry -702.90

P/EBITDA

-8.24

Sector -4.39

Industry -4.39

P/EBIT

-8.24

Sector -4.73

Industry -4.73

P/Total Assets

2.45

Sector 1.49

Industry 1.49

P/Net Current Assets

2.60

Sector -11.70

Industry -11.70

P/Working Capital

2.54

Sector -3.19

Industry -3.19

EPS

-0.55

Sector -2.14

Industry -2.14

BVPS

1.84

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-29.98%

Sector -65.14%

Industry -65.14%

ROA

-28.27%

Sector -65.53%

Industry -65.53%

ROIC

-4,387.58%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

29.52

Sector 2.90

Industry 2.90

Net Debt / EBITDA

14.51

Sector -6.07

Industry -6.07

Net Debt / EBIT

14.51

Sector -8.26

Industry -8.26

Net Debt / Equity

-1.05

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.94

Sector 0.41

Industry 0.41

Liabilities/Assets

0.06

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

-13.21%

Sector -

Industry -

Fundamentals RLMD

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
RLMD Relmada Therapeutics Inc.	$4.83	627.41%	0.00%	-8.66	2.60	-29.98%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

RLMD Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Relmada Therapeutics

Relmada Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

14 years

Founded: 2012

2014

Time since IPO - 12 years

14

Employees

Relmada Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $536.48 million, with shareholders equity totaling $206.56 million.

The company employs approximately 14 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Relmada Therapeutics Inc. reported $- in revenue, generating net income of $-61.92 million.

Key financial metrics include a P/E ratio of -8.66, a price-to-book (P/B) ratio of 2.60, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker RLMD.

Market cap

$536.48 million

Net worth

$206.56 million

$206,560,000.00

Assets

$219.06 million

$219,060,000.00

Total Shares Outstanding

112.00 million

112,000,000

Average Daily Trading Volume

$1.96 million

$1,956,133.88

Sector

Health Care

Industry

Biotechnology

RLMD

RLMD revenue and profits

Financial Results RLMD

DRAG THE FRAME TO SEE MORE DATA

RLMD cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Relmada Therapeutics (RLMD) today?

A cotação de Relmada Therapeutics (RLMD) hoje está em US$ 4.83, com uma variação de 677.65% em relação ao último ano. A cotação de Relmada Therapeutics (RLMD) iniciou o ano negociando na casa dos US$ 4.83 e hoje está em US$ 4.83. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Relmada Therapeutics (RLMD) e dados de ações do Ibovespa e mercados internacionais.

Quando Relmada Therapeutics (RLMD) paga dividendos?

Relmada Therapeutics (RLMD) não distribuiu dividendos no último ano.

Is Relmada Therapeutics (RLMD) a good investment?

Atualmente, Relmada Therapeutics (RLMD) está cotada a US$ 4.83, com um P/L de -8.66, representando um desvio de -330% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 677.65 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 677.65%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Relmada Therapeutics (RLMD) stock?

Investir em ações de Relmada Therapeutics (RLMD) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Relmada Therapeutics (RLMD) yield today?

A rentabilidade de Relmada Therapeutics (RLMD) foi de -7.03% no último mês, 677.65% no último ano e -80.12% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Relmada Therapeutics (RLMD) hoje, o investimento total seria de US$ 483.00, com base na cotação atual de US$ 4.83.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 3,756.05
Em 5 anos: US$ 96.02
Em 10 anos: US$ 355.63

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

RLMD

Relmada Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment RLMD

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING RLMD WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Relmada Therapeutics

Relmada Therapeutics Inc.

United States

14 years

2014

14

PROFIT X PRICE RLMD

Financial Results RLMD

RLMD cash flow

Asset, Revenue and Profit Growth - RLMD

RLMD balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions